Patients With Incident Acute Coronary Syndrome Are Often Potentially Eligible for PCSK9 Inhibitor Treatment
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Circulation: Cardiovascular Quality and Outcomes
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Lipid Testing, Lipid-Modifying Therapy, and PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Eligibility in 27 979 Patients With Incident Acute Coronary Syndrome
Circ Cardiovasc Qual Outcomes 2021 Apr 05;[EPub Ahead of Print], B Sarak, A Savu, P Kaul, FA McAlister, RC Welsh, AT Yan, SG GoodmanFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.